J-WDMC Precision Therapeutics 

A Multi-Functional, Next-Gen ADC & Immunotherapy Drug Binding Microtubules to Cure Currently Incurable Cancer 

Tumor-Specific Universal Cancer Drugs with Zero Normal Tissue Binding

        Our invention “Tumor-Specific-Targeting-Platform” specifically target tumor, does not bind to normal tissues: It is low toxicity to patients. Its low DLT (dose-limiting toxicity) can maximize drug dose and therapy efficacy.  It can reduce cancer therapy-induced patient death, side-effects, complex diseases, lifespan shortening & secondary cancers.

          In comparison, current anticancer drugs/CAR-T targeting to CEACAM5, CEACAM6, Nectin-4, BCMA, CD19, CD20, CD30, CD38, CD40, CD44v6, CD47, CD70, CD73, CTLA-4, FRα, EGFR, Caprin-1, GPC3, Integrin, PD-L1, Trop2, CLDN18.2, PSMA, HER2, HER3, DLL3, TIGIT, PTK7, VEGF, c-Met, B7-H3, & B7-H4…etc., developing by AbbVie, AstraZeneca, BMS, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Roche, & Takeda…etc., show strong binding to normal tissues. These drugs can lead to severe organ damages and life-threatening toxicities. Also, their high DLTs limit drug dose in patients, thus they have low therapy efficacies.

A Multi-Functional, Next-Gen ADC & Immunotherapy Drug Binding Microtubules to Cure Currently Incurable Cancer

Current drugs often only give late-stage cancer patients a few extra months before they die.

Only 1%〜2% of administered drugs (ADCs, small molecules, immunotherapy-, chemotherapy-drugs) doses accumulate in tumors, due to tumor efflux pumps expel drug, limited binding specificity, and tumor antigen mutation.

Current ADC drug antigens often are pure membrane ligands like EGFR that do not bind to cellular structure proteins, making them easily expelled into vessels by tumor cells, thus have low tumor-toxicity, damage normal organs, and drug resistance occurs easily.

We developed a Multi-Functional, Next-Gen ADC drug specifically binding to a tumor surface antigen & microtubules, powered by a native anti-tumor M2 macrophages (M2-TAM) immunotherapy to cure hard-to-treat cancer.

# Breakthroughs

1. Tumor-Specific Targeting: Our drug specifically targets tumors with zero normal tissue binding. This excludes toxic drug side effects in patients, maximizing drug dose and therapy efficacy.

2. Resisting Tumor Efflux Pumps: Besides binding to a tumor surface antigen, our drug also binds to microtubules in tumor cells, thus resist to tumor efflux pumps. (1) This accumulates a massive drug dose inside tumor cells to maximize tumor cell-killing. (2) Resisting tumor efflux further prevents our drug from flowing into blood vessels and normal tissues, preventing drug toxicity in normal organs, as attached image shown.

3. Resisting Mutation Escape: Our drug targets a microtubule-binding protein which is also located on tumor surface. It is essential for tumor cell proliferation (mitosis) and survival. Tumor cells cannot mutate it to resist our ADC drug.

4. Native Anti-M2-TAM Immunotherapy: Our ADC drug directly kills tumor cells and powered by a native M2-TAM immunotherapy that targets tumor microenvironment:

(1) Dual-Action & High Loading in Tumor: No need for costly or complex genetic engineering and multi-payload ADC design.

(2) Stops M2-TAM-induced regulatory T cells (Tregs) that protect the tumor's immunosuppressive shield.

(3) Reverses M2-TAM-induced CD8+ T cell dysfunction, reactivating them to kill tumor cells.

(4) Blocks M2-TAM-, MDSC-, and CAF-mediated tumor immunosuppression and their PD-L1/PD-1 tumor anti-T cell attack machinery.

(5) Stops M2-TAM-mediated tumor growth, drug resistance, angiogenesis, and tissue remodeling.

# One-Target, Multi-Benefit: 

Our drug only targets an antigen. yes it can directlty kill tumor cells, attack tumor's multiple immunosuppressive shields, unlock the gate of tumor drug resistance, maximize drug loading in tumor, and resist to tumor mutation escape at once. Thus, the drug has great potential to overcome refractory therapy resistance and cure currently incurable cancer. 

We filed patents in 2026 to get 20+7 years patent protection in most countries worldwide. Utility of our platform:

1.      Antibody-image-guided precision cancer surgery.

2.      Antibody-image-guided precision external beam radiation therapy (EBRT).

3.      Antibody-targeted agent for Boron Neutron Capture Therapy (BNCT).

4.      Antibody-targeted proton and heavy-ion therapy.

5.      Antibody-contrast-enhanced CT, MRI, & PET tumor imaging. 

6.      CAR-T therapy and CAR-NK therapy.

7.      Antibody-cell conjugates (ACCs).

8.      T-cell receptor-mimic (TCRm) antibodies.

9.      Bispecific T-cell Engagers (BiTEs): bispecific antibody for cancer immunotherapy.

10.  Degrader-Antibody Conjugates (DACs) for targeted protein degraders to kill tumors.

11.  Antibody-drug conjugates (ADCs), antibody radio-drug conjugate (ARC), peptide-drug conjugates.

12.  Cancer vaccines: DNA, RNA, protein, & peptide cancer vaccines.

13.  Nanoparticles for targeted magnetic hyperthermia therapy & in situ vaccination.

14. Antibody-targeted ultrasound cancer therapy.

15.  Antibody-image-guided precision Interventional Oncology Therapy.

Contact: info@j-wdmc.com